Irene Rossmer, MD
Surgical Oncology · Summit, NJNPI 1780837849
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $421 and has fallen 68.0% since, to $135 in 2025. That places this record below the midpoint for surgical oncology clinicians in NJ, where the typical reported total is $1,132.
Across 62 payments — averaging $19.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mirati Therapeutics, Inc.$153
- Pharmacosmos Therapeutics Inc.$109
- AbbVie$103
- Karyopharm Therapeutics Inc.$94
- Mentor Worldwide LLC$58
- Bayer$56
- plus $651 from 25 others
What the payments were for
- Food & beverage$1,224100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mirati Therapeutics, Inc. | 9 | $153 |
| Pharmacosmos Therapeutics Inc. | 1 | $109 |
| AbbVie | 6 | $103 |
| Karyopharm Therapeutics Inc. | 6 | $94 |
| Mentor Worldwide LLC | 1 | $58 |
| Bayer | 3 | $56 |
| Seagen Inc. | 3 | $48 |
| Astellas Pharma US Inc | 2 | $41 |
| AstraZeneca | 2 | $41 |
| Medtronic | 1 | $40 |
| Sanofi | 2 | $38 |
| Cumberland Pharmaceuticals, Inc. | 2 | $36 |
| Axogen | 1 | $35 |
| Daiichi Sankyo Inc. | 2 | $33 |
| Merck | 2 | $33 |
| Genmab U.S., Inc. | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Amgen | 2 | $27 |
| Smith+Nephew | 1 | $25 |
| Angiodynamics, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Rigel Pharmaceuticals, Inc. | 1 | $17 |
| Tersera Therapeutics LLC | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Galvanize Therapeutics, Inc | 1 | $16 |
| Taiho Oncology, Inc. | 1 | $15 |
| Morphosys, US Inc. | 1 | $14 |
| GSK | 1 | $14 |
| EMD Serono, Inc. | 1 | $14 |
| Incyte Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monoferric$109
How this compares
$1,224 in reported general payments places this provider in the 50th percentile of 59 surgical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other surgical oncology in Summit
- Margaret SaccoSummit$392
- Thangamani SeenivasanSomerville$22K
- John CunninghamBerkeley Heights$20K
- Manpreet KohliLong Branch$20K
- Haejin InNew Brunswick$12K
- Anjeanette BrownCape May Court House$11K
- Marc FromerBrick$9K
- Russell LanganLivingston$9K
- Elsa PichardoPlainsboro$8K
- Denise Johnson MillerNeptune$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.